BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33097398)

  • 1. Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomy.
    Stolzenbach LF; Knipper S; Mandel P; Ascalone L; Deuker M; Tian Z; Heinzer H; Tilki D; Maurer T; Graefen M; Karakiewicz PI; Steuber T
    Urol Oncol; 2021 Apr; 39(4):234.e1-234.e7. PubMed ID: 33097398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center.
    Würnschimmel C; Wenzel M; Wang N; Tian Z; Karakiewicz PI; Graefen M; Huland H; Tilki D
    Urol Oncol; 2021 Dec; 39(12):830.e17-830.e26. PubMed ID: 34092484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
    Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
    PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy.
    Preisser F; Wang N; Abrams-Pompe RS; Chun FK; Graefen M; Huland H; Tilki D
    Urol Oncol; 2022 Apr; 40(4):161.e9-161.e14. PubMed ID: 34973856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
    Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
    Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
    Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
    Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion.
    Barletta F; Tappero S; Morra S; Incesu RB; Cano Garcia C; Piccinelli ML; Scheipner L; Baudo A; Tian Z; Gandaglia G; Stabile A; Mazzone E; Terrone C; Longo N; Tilki D; Chun FKH; de Cobelli O; Ahyai S; Carmignani L; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2023 Dec; 21(6):e461-e466.e1. PubMed ID: 37365054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT2-pT3a N0R0) and outcomes.
    Mearini L; Nunzi E; Bini V; Lepri L; Bruno R; Porena M
    Urologia; 2014; 81(2):125-32. PubMed ID: 24474543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
    Tilki D; Preisser F; Tennstedt P; Tober P; Mandel P; Schlomm T; Steuber T; Huland H; Schwarz R; Petersen C; Graefen M; Ahyai S
    BJU Int; 2017 May; 119(5):717-723. PubMed ID: 27743493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.
    Seyedin SN; Mitchell DL; Mott SL; Russo JK; Tracy CR; Snow AN; Parkhurst JR; Smith MC; Buatti JM; Watkins JM
    Pathol Oncol Res; 2019 Jan; 25(1):209-215. PubMed ID: 29079967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
    Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
    Antunes HP; Parada B; Carvalho J; Eliseu M; Jarimba R; Oliveira R; Tavares-da-Silva E; Figueiredo A
    Arch Ital Urol Androl; 2018 Sep; 90(3):191-194. PubMed ID: 30362685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
    Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
    Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oncological outcomes after laparoscopic radical prostatectomy.
    Hruza M; Bermejo JL; Flinspach B; Schulze M; Teber D; Rumpelt HJ; Rassweiler JJ
    BJU Int; 2013 Feb; 111(2):271-80. PubMed ID: 22757970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes.
    Ledezma RA; Negron E; Razmaria AA; Dangle P; Eggener SE; Shalhav AL; Zagaja GP
    World J Urol; 2015 Nov; 33(11):1689-94. PubMed ID: 25701128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.